Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December. Full details of the poster presentation are below:
Author: Alex Molassiotis, Matti Aapro, Alessandro Alonzi, Marika Chrápavá, Karin Jordan Eric J. Roeland, Lee Schwartzberg, Carole Terrasanta, Silvia Olivari Tilola, George Dranitsaris
Session: Poster session, 03 December, 18:00 – 18:45
Dr Silvia Sebastiani, Helsinn Group Head of Medical Affairs, commented: “We are pleased to present the design of this important ongoing study at the ESMO Asia congress. Despite the array of effective antiemetics, CINV still represents a huge unmet need in clinical practice. To further the goal of CINV prevention for all patients undergoing emetogenic chemotherapy, it is important to explore ways to optimize antiemetic selection, including exploring factors that may increase CINV risk for patients.” Prof. Alex Molassiotis, Pro Vice Chancellor and Dean, University of Derby, UK and Scientific Lead of the MyRisk study added: “In patients receiving moderately emetogenic chemotherapy (MEC), antiemetic guidelines generally recommend a setron + dexamethasone (DEX). However, one guideline committee (the National Comprehensive Cancer Network (“NCCN”)) recognized that this approach is inadequate prophylaxis for many patients and included an NK1 RA-containing option selectively for those with individual emetic risk factors2. MyRisk is the first study prospectively exploring the role of NK1 RA-containing regimen, Akynzeo in this case, in patients receiving MEC who have additional risk factors.” For additional information please see the EU Summary of Product Characteristics.
AKYNZEO® (netupitant 300mg/palonosetron 0.5mg) capsules was approved in October 2014 in the United States and is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO® (fosnetupitant 235mg/palonosetron 0.25) for injection was approved in April 2018 and AKYNZEO® injection was approved in May 2020 in the United States. Each is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Warnings and Precautions:
Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4 isoenzyme. The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO®. The inhibitory effect on CYP3A4 can last for multiple days. Avoid concomitant use of AKYNZEO® in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO®. Use in Specific Populations:
Avoid use in pregnancy, limited data is available, may cause fetal harm.
For more information about AKYNZEO® please see the full US Prescribing Information Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases. Helsinn is a third-generation family-owned company, that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. Helsinn’s unique business model enables it to in-license or acquire assets at a late stage of development. It has a commercial presence in 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its network of long-standing trusted partners. Helsinn also has a fully integrated supply chain and product development through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd. Helsinn plays an active and central role in promoting social transformation in favor of people and the environment. Sustainability is at the heart of everything we do, which is reinforced in the company’s strategic plan by a commitment to sustainable growth.
To learn more about Helsinn please visit www.helsinn.com
1 Roila F. et al. Ann Oncol. 2016 Sep;27(suppl 5):v119-v133. MASCC/ESMO Antiemetic Guideline 2016 V.1.4 last update July 2019. Available at: http://www.mascc.org/ /
2 NCCN: National Comprehensive Cancer Network; NCCN Clinical Practice Guidelines in Oncology; Version 2.2022. Available at: www.nccn.org 3 Hesketh J. et al. J Clin Oncol. 2020 Aug 20;38(24):2782-2797. doi: 10.1200/JCO.20.01296. Epub 2020 Jul 13
Paola Bonvicini, Group Head of Communication
Tel: +41 (0) 91 985 21 21
Email: Info-hhc@helsinn.com
For more information, please visit www.helsinn.com and follow us on Twitter and LinkedIn